

Title Asthma treatments

Reference Number: RDF2469-24

Date of Response: 15/04/24

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Q1. How many patients have been treated (for any condition) in the last 4 months* with: Answers:

Treatment	Patients
Benralizumab	95
Dupilumab	181
Omalizumab	102
Reslizumab	*<5
Mepolizumab	33
Tezepelumab	32

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

Answers:

Treatment	Patients
Age 6-11	12
Age 12-17	15
Age 18 and above	416

Q3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:

Answers:

Treatment	Patients
Dupilumab	12
Omalizumab	37

*<5 - Section 40(2):

Please note that in accordance with Section 40 (2) where activity is 5 or less than 5, the Trust is unable to provide the exact information. We consider the data exempt on the following grounds:

The Trust considers that disclosure of the information risks identifying individuals. The reason for this is that the number of patients for which this applies is very low. This and the fact that the data requested relates to the RDUH NHS Trust only and

therefore relates to patients treated in a specific location (rather than covering a larger geographical area), increases the risk of identification or self-identification. The Trust's view is that Section 40(2) is applicable because disclosure of information which could lead to a patient being identified would be a breach of the patient's rights under the Data Protection Act Data Protection Principles set out in Schedule 1 of the GDPR, namely Principle 1.